Nektar Therapeutics (NKTR) Scheduled to Post Earnings on Thursday

Nektar Therapeutics (NASDAQ:NKTR) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Monday, March 4th. The biopharmaceutical company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.01). The business had revenue of $23.89 million for the quarter, compared to analyst estimates of $17.09 million. Nektar Therapeutics had a negative return on equity of 96.80% and a negative net margin of 306.31%. During the same period in the previous year, the company earned ($0.32) earnings per share. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Stock Performance

Shares of NASDAQ:NKTR opened at $1.50 on Wednesday. The company has a market cap of $275.43 million, a P/E ratio of -1.03 and a beta of 0.71. Nektar Therapeutics has a 52-week low of $0.41 and a 52-week high of $1.79. The stock’s 50-day moving average is $1.15 and its 200-day moving average is $0.76.

Wall Street Analyst Weigh In

NKTR has been the topic of a number of research analyst reports. StockNews.com assumed coverage on shares of Nektar Therapeutics in a report on Friday, January 26th. They set a “hold” rating on the stock. William Blair reiterated a “market perform” rating on shares of Nektar Therapeutics in a report on Tuesday, March 5th. Finally, Jefferies Financial Group increased their price target on Nektar Therapeutics from $0.50 to $1.00 and gave the company a “hold” rating in a research note on Wednesday, March 6th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Nektar Therapeutics has a consensus rating of “Hold” and an average target price of $3.50.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.